This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teichman, S. L. Articles by Frohman, L. A. Search for Related Content PubMed PubMed Citation Articles by Teichman, S. L. Articles by Frohman, L. A. Related Collections Neuroendocrinology and Pituitary Endocrine Oncology

Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults

WinPharm Associates (S.L.T., A.N.), Alamo, California 94507; ConjuChem, Inc. (B.L., C.G., J.-P.C.), Montréal, Québéc, Canada; and Section of Endocrinology, Department of Medicine, University of Illinois (L.A.F.), Chicago, Illinois 60612

Address all correspondence and requests for reprints to: Dr. Lawrence A. Frohman, Section of Endocrinology, Department of Medicine, University of Illinois, 1819 West Polk Street (M/C 640), Chicago, Illinois 60612. E-mail: frohman{at}uic.edu.

Context: Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.

Objective: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog.

Design: The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.

Setting: The study was performed at two investigational sites.

Participants: Healthy subjects, ages 21–61 yr, were studied.

Interventions: CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.

Main Outcome Measures: The main outcome measures were peak concentrations and area under the curve of GH and IGF-I; standard pharmacokinetic parameters were used for CJC-1295.

Results: After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9–11 d. The estimated half-life of CJC-1295 was 5.8–8.1 d. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported.

Conclusions: Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 µg/kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC-1295 as a therapeutic agent.

This article has been cited by other articles:

				D. Gautam, J. Jeon, M. F. Starost, S.-J. Han, F. F. Hamdan, Y. Cui, A. F. Parlow, O. Gavrilova, I. Szalayova, E. Mezey, et al. Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth PNAS, April 14, 2009; 106(15): 6398 - 6403. [Abstract] [Full Text] [PDF]

				F. Peter, C. Savoy, H.-J. Ji, M. Juhasz, M. Bidlingmaier, and P. Saenger Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency Eur. J. Endocrinol., March 1, 2009; 160(3): 349 - 355. [Abstract] [Full Text] [PDF]

				M. G.-S. Frutos, L. Cacicedo, C. Fernandez, D. Vicent, B. Velasco, H. Zapatero, and F. Sanchez-Franco Insights into a role of GH secretagogues in reversing the age-related decline in the GH/IGF-I axis Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1140 - E1152. [Abstract] [Full Text] [PDF]

				M. Ionescu and L. A. Frohman Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4792 - 4797. [Abstract] [Full Text] [PDF]

				M. Alba, D. Fintini, A. Sagazio, B. Lawrence, J.-P. Castaigne, L. A. Frohman, and R. Salvatori Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1290 - E1294. [Abstract] [Full Text] [PDF]